Subclinical vascular inflammation in subjects with normal weight obesity and its association with body fat: an 18F-FDG-PET/CT study. by 媛뺤떊�븷 et al.
CARDIO
VASCULAR 
DIABETOLOGY
Kang et al. Cardiovascular Diabetology 2014, 13:70
http://www.cardiab.com/content/13/1/70ORIGINAL INVESTIGATION Open AccessSubclinical vascular inflammation in subjects with
normal weight obesity and its association with
body Fat: an 18 F-FDG-PET/CT study
Shinae Kang1,2, Chanhee Kyung1, Jong Suk Park1,2, Sohee Kim1, Seung-Pyo Lee3, Min Kyung Kim1, Hye Kyung Kim4,
Kyung Rae Kim1, Tae Joo Jeon5* and Chul Woo Ahn1,2*Abstract
Background: Although body mass index (BMI) is the most widely accepted parameter for defining obesity, recent
studies have indicated a unique set of patients who exhibit normal BMI and excess body fat (BF), which is termed
as normal weight obesity (NWO). Increased BF is an established risk factor for atherosclerosis. However, it is unclear
whether NWO subjects already have a higher degree of vascular inflammation compared to normal weight lean (NWL)
subjects; moreover, the association of BF with vascular inflammation in normal weight subjects is largely unknown.
Methods: NWO and NWL subjects (n = 82 in each group) without any history of significant vascular disease were
identified from a 3-year database of consecutively recruited patients undergoing 18 F-fluorodeoxyglucose positron
emission tomography/computed tomography (18 F-FDG-PET/CT) at a self-referred Healthcare Promotion Program. The
degree of subclinical vascular inflammation was evaluated using the mean and maximum target-to-background ratios
(TBRmean and TBRmax) of the carotid artery, which were measured by 18 F-FDG-PET/CT (a noninvasive tool for
assessing vascular inflammation).
Results: We found that metabolically dysregulation was greater in NWO subjects than in NWL subjects, with a
significantly higher blood pressure, higher fasting glucose level, and worse lipid profile. Moreover, NWO subjects exhibited
higher TBR than NWL subjects (TBRmean: 1.33 ± 0.16 versus 1.45 ± 0.19, p < 0.001; TBRmax: 1.52 ± 0.23 versus 1.67 ± 0.25,
p < 0.001). TBR was significantly associated with total BF (TBRmean: r = 0.267, p = 0.001; TBRmax: r = 0.289, p < 0.001), age
(TBRmean: r = 0.170, p = 0.029; TBRmax: r = 0.165, p = 0.035), BMI (TBRmean: r = 0.184, p = 0.018; TBRmax: r = 0.206,
p = 0.008), and fasting glucose level (TBRmean: r = 0.157, p = 0.044; TBRmax: r = 0.182, p = 0.020). In multiple linear
regression analysis, BF was an independent determinant of TBRmean and TBRmax, after adjusting for age, BMI, and fasting
glucose level (TBRmean: regression coefficient = 0.020, p = 0.008; TBRmax: regression coefficient = 0.028, p = 0.005).
Compared to NWL, NWO was also independently associated with elevated TBRmax values, after adjusting for
confounding factors (odds ratio = 2.887, 95% confidence interval 1.206–6.914, p = 0.017).
Conclusions: NWO is associated with a higher degree of subclinical vascular inflammation, of which BF is a major
contributing factor. These results warrant investigations for subclinical atherosclerosis in NWO patients.
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According to National Health and Nutrition Examination
Survey (NHANES) and Korean National Health and Nutri-
tion Examination Survey (KNHANES) data, the prevalence
of obesity has increased to 30% in USA [1] and 30.9% in
Korea [2]. Obesity is a well-known cause of cardiovascular
disease (CVD) and all-cause mortality [3-5]. Classically,
obesity has been defined as an excess of body weight com-
pared to the height, which has been simplified as a single
value, termed as the body mass index (BMI) [6].
The limitation of BMI is that it can misclassify subjects
who have lower lean mass but higher fat mass as non-
obese [7]. This inherent limitation of BMI in the accurate
diagnosis of obesity is observed to a greater extent among
Asians and the elderly, who commonly have lower lean
body mass [8-10]. Consequently, the new concept of nor-
mal weight obesity (NWO) had been proposed. NWO
subjects have normal BMI and an elevated body fat per-
centage (BF%) [11], and may be at a high risk for cardio-
metabolic disease [12-16]. Considering that fat itself is a
major contributing factor on CVD in obese subjects [5],
methods to estimate the risk of CVD associated with BF%
or absolute fat mass can be accurate and helpful for
assessing early cardiometabolic disease risk in the NWO
population.
Inflammation is a major driving factor of atherosclerosis
progression [17] and a major determinant of plaque
rupture [18], the results of which may be devastating.
Therefore, accurate assessment of vascular inflamma-
tion rather than the extent of luminal stenosis may be
more essential for preventing CVD [19]. The uptake of
18 F-fluorodeoxyglucose (18 F-FDG) in the vessel corre-
lates very well with the degree of macrophage infiltra-
tion [20], because the macrophages preferentially utilize
glucose, particularly under anaerobic conditions [21,22].
Based on these findings, the usefulness of 18 F-FDG
positron emission tomography/computed tomography
(18 F-FDG-PET/CT) has been demonstrated when evaluat-
ing vascular inflammation [23-26]. Therefore, in the present
study, we aimed to determine the degree of subclinical vas-
cular inflammation in NWO subjects and the contributing
factors associated with the inflammation. Hence, we used a
large database consecutively recruited from the patients
undergoing 18 F-FDG-PET/CT from a self-referred health-
care promotion program to identify patients without any
history of clinical cerebrovascular disease.
Methods
Study design and population
This cross-sectional study was designed to evaluate the ef-
fect of BF on vascular inflammation of the carotid arteries
in subjects with a normal BMI. Asymptomatic subjects self-
referred for 18 F-FDG-PET/CT examination from March
2010 to February 2013 in a health checkup program atthe Health Promotion Center, Gangnam Severance Hos-
pital, were consecutively registered (N = 1003; Men: n =
602; Women: n = 401). All subjects underwent a medical
examination, including clinical history, physical examin-
ation, blood analysis, abdominal ultrasound, and 18 F-FDG-
PET/CT.
We divided the whole population by gender-specific
BF% tertiles and defined NWO subjects as those with a
normal BMI (18.5–24.9 kg/m2) and the highest tertile
of BF% (Men, ≥23.5%, Women, ≥29.2%) in line with a
previous study15, thus yielding 89 NWO subjects (Men:
N = 38; Women: N = 51). Subjects who were previously
diagnosed with diabetes mellitus and/or taking anti-
diabetic medication were excluded. Moreover, subjects
with previously diagnosed malignancy within 5 years of
PET/CT examination, chronic inflammatory disease, or
other previous disease of the carotid artery were ex-
cluded. Finally, 82 NWO subjects were included in the
present study. Moreover, 82 control normal weight lean
(NWL) subjects (Men, <23.5%; Women, <29.2%)—i.e.,
normal BMI subjects who were in the lower two tertiles
for gender-specific BF%—were randomly selected from
sex-matched subjects using random numbers uniformly
distributed between 0 and 1 (Figure 1). In addition, we
constructed another database comprising 63 subjects each
in the NWL and NWO groups who were matched for
sex and BMI values using greedy matching techniques.
The exclusion criteria of the NWL subjects were iden-
tical to those for the NWO subjects. The protocol of
this study was approved by the institutional review
board of Gangnam Severance Hospital, and all subjects
provided written informed consent for the 18 F-FDG-PET/
CT examination.
Questionnaire
The current and past medical history of disease, medica-
tion, presence of CVD risk factors (smoking, alcohol, and
family history of premature CVD), and other information
on medico-social history were self-reported via a routine
questionnaire before the health checkup.
Anthropometric measurement
All subjects were requested to fast for more than 8 hours
before all biochemical and anthropometric examinations.
Body weight was measured by electronic load to the
nearest 0.01 kg, with the parents wearing a light gown
without shoes for the health examination. Height was
measured to the nearest 0.1 cm. BMI was calculated as
the weight in kilograms divided by the square of height
in meters (kg/m2). The BF%, total body fat, visceral fat,
subcutaneous fat, and muscle mass were measured using
the bioelectrical impedance (BI) body composition analyzer
X-scan plusII (Jawon Medical, Seoul, Korea) [27]. In brief,
the tetra-polar electrode method with 8 touch electrodes
2010.03.01 ~ 2013.02.28
Patients taken 18F-FDG-PET/CT 
in the health promotion center of Gangnam Severance Hospital
N=1003
Normal BMI & aged between 20 -79 years old 
N=623 (Men:325, Women:298)
1st & 2nd lower tertile of BF% 
(men<23.5%)
N=287
1st & 2nd lower tertile of BF% 
(women<29.2%)
N=247
NWL men
N=263
NWL women
N=229
exclusion criteria 
(DM, other 
cardiovascular 
disease, etc.)
N=18 
380 patients excluded by BMI criteria 
(<18.5kg/m2 2)
exclusion criteria 
(DM, other 
cardiovascular 
disease, etc.)
N=24 
Highest tertile of BF% 
(men 23.5%)
N=38
Highest tertile of BF%
(women 29.2%)
N=51
exclusion criteria 
(DM, other 
cardiovascular 
disease, etc)
N=2
exclusion criteria 
(DM, other 
cardiovascular 
disease, etc.)
N=5
NWO men
N=33
NWO women
N=49
NWO (normal weight obesity)
N=89
NWL (normal weight lean)
N=534
Randomly selected, age-
matched NWL men
N=33
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Figure 1 Schematic diagram and the process of the registration of subjects. 18 F-FDG-PET/CT, 18 F-fludeoxyglucose positron emission tomography/
computed tomography; BMI, body mass index; NWL, normal weight lean; NWO, normal weight obesity; BF, body fat; DM, diabetes mellitus.
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the BI value in the abdominal area, which was evaluated by
the current intercrossing between each hand and foot. By
using the waist-to-hip ratio, body weight, height, age, sex,
and the BI value of the abdominal area, the Jawon Medical
Company created a formula specific for Korean individuals
to calculate the visceral fat amount. The subcutaneous fat
amount was estimated by excluding the visceral fat from
the total fat amount [28,29]. Systolic and diastolic blood
pressure was measured using BP203RV II (Colin Corp.,
Aichi, Japan) after resting for more than 15 min in the sit-
ting position. The presence of fatty liver was assessed using
a Philips IU-22 Ultrasound system (Philips Healthcare,
Andover, MA) by an expert radiologist.Biochemical measurement
Glucose was measured by the glucose oxidase method
using a 747 Automatic Analyzer (Hitachi, Tokyo, Japan).
Glycated hemoglobin A1c (HbA1c) level was measured
by high-performance liquid chromatography (Cobas Integra
800, Roche, Mannheim, Germany). The levels of total
cholesterol, high-density lipoprotein cholesterol (HDL-cholesterol), triglyceride, C-reactive protein (CRP), aspar-
tate aminotransferase (AST), and alanine aminotransfer-
ase (ALT) were measured by an enzymatic colorimetric
method (Daiichi, Hitachi). Low-density lipoprotein choles-
terol (LDL-cholesterol) content was calculated according
to the Friedewald formula.18 F-FDG-PET/CT imaging and image analysis
All patients fasted at least 8 h before the injection of
18 F-FDG, after ensuring that serum glucose levels at
this time point did not exceed 150 mg/dL. The injec-
tion dose of 18 F-FDG was 5.18 MBq/kg (0.14 mCi/kg).
18 F-FDG-PET images were obtained using a standard
PET/CT scanner (Biograph TruePoint 40, Siemens Health-
care, Erlangen, Germany) and all data were acquired in the
3D mode with a 1.5-min scan time per bed. Tomographic
PET images were reconstructed by using an iterative
method involving ordered subset expectation maximization,
under the condition of 2 iterations and 21 subsets. The
matrix of reconstructed PET images using this method
was 128 × 128, and the slice thickness was 5 mm. Low-
dose CT scans for attenuation correction and identification
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the PET scan.
Image analysis was conducted using a dedicated PET/
CT workstation (Syngo 2009A, Siemens Healthcare) ac-
cording to previous reports [20,24-26]. In detail, for exact
measurement of the carotid artery and jugular vein, the
overall diameter, course, and variation of cervical vascula-
ture were first reviewed using CT images, after which the
metabolic activity of the artery and vein was estimated by
using PET/CT fusion images prior to region of interest
(ROI) measurements. A circular ROI was used in most
slices of the carotid arteries, whereas an oval or circular
ROI was used for the jugular vein depending on its con-
tour. Each ROI was intended to include the entire wall of
the artery and vein. The measurement of the uptake value
(SUV) was started from the highest level of the common
carotid artery before bifurcation to the external and in-
ternal carotid branches (mostly around the level of the
hyoid bone), and 10 ROIs were consecutively measured
from the inferior level up to the origin of the carotid ar-
tery from the aortic arch. Eight ROIs were used to meas-
ure the jugular vein SUV, and their locations were similar
to those of the carotid artery. The maximal (SUVmax)
and mean SUV (SUVmean) were measured in the carotid
artery and the jugular vein, respectively, after which the
target-to-background ratio (TBR) was calculated using the
following equations: Mean TBR (TBRmean) = (mean SUV
of carotid artery)/(mean SUV of jugular vein); Maximum
TBR (TBRmax) = (maximum SUV of carotid artery)/
(mean SUV of jugular vein) [20,24-26].Statistical analyses
Anthropometric, clinical, and biochemical data are pre-
sented as the mean ± standard deviation (SD) for con-
tinuous variables and absolute numbers (percentage) for
categorical variables. An independent two-sample t-test
or paired sample t-test was used to evaluate the differ-
ences in the continuous variables between NWL and
NWO subjects after testing each variable for normality
with the Shapiro-Wilk test. The χ2 test or Fisher’s exact
test was used to compare categorical variables between
the NWL and NWO groups, as appropriate. The degree
of a relationship between putative CVD risk factors and
TBRmean or TBRmax was expressed by Pearson’s cor-
relation coefficient (r). Multiple stepwise linear regres-
sion analysis was used to determine the independent
predictors of TBRmean and TBRmax. Logistic regression
models were analyzed to evaluate the odds ratio (OR)
for TBRmax elevation in the NWO group compared to
the NWL group. All statistical analyses were performed
using adequate software (SPSS version 20.0, Chicago,
IL). A p value of <0.05 was considered to be statistically
significant.Results
Clinical and biochemical characteristics of the
study population
The mean age of the subjects was 54 years, and 18% of the
subjects had hypertension. The NWO subjects had a higher
BMI, larger waist-to-hip ratio, and greater amount of vis-
ceral and subcutaneous fat. There was no difference in total
muscle mass between the groups. NWO subjects had sig-
nificantly higher systolic and diastolic BP than NWL sub-
jects. Although there was no difference in HbA1c levels,
the fasting plasma glucose level was significantly higher in
the NWO group. In addition, NWO subjects had higher
serum triglyceride and lower HDL-cholesterol levels. No
differences in current anti-hypertensive drug, statin, and
anti-platelet use were noted between the groups. Detailed
comparisons of each parameter are summarized in Table 1.
Moreover, we analyzed these clinical and biochemical
parameters after dividing the study population based on
gender. The difference in the metabolic profile tended
to be significant between the female subjects in the
NWO and NWL groups, whereas certain parameters
such as blood pressure and CRP were not significantly
different in the male subjects between the NWO and
NWL groups (Table 2).
Evaluation of vascular inflammation by 18 F-FDG-PET/CT
between NWL and NWO subjects
Compared to the NWL group, the NWO group had a sig-
nificantly higher SUVmean and SUVmax at the carotid ar-
tery (SUVmean: 1.53 ± 0.31 versus 1.64 ± 0.31, p = 0.024;
SUVmean: 1.75 ± 0.36 versus 1.90 ± 0.38, p = 0.009) (Table 3,
Figures 2A and B, Figure 3). However, there was no differ-
ence in the SUVmean at the jugular vein between the two
groups. TBRmean and TBRmax—the corrected values of
carotid SUVmean and SUVmax divided by the SUVmean
of the jugular vein in each individual, respectively—were
also higher in the NWO population (TBRmean: 1.33 ± 0.16
versus 1.45 ± 0.19, p < 0.001; TBRmax: 1.52 ± 0.23 versus
1.67 ± 0.25, p < 0.001) (Table 3, Figures 2C and D). As the
degree of vascular inflammation may be affected by the co-
existence of hypertension or statin use, we also analyzed
the degree of carotid inflammation after excluding subjects
with these factors. However, the difference was consistently
significant even in patients without anti-hypertensive or sta-
tin use (TBRmean: 1.33 ± 0.16 versus 1.44 ± 0.21, p < 0.001;
TBRmax: 1.52 ± 0.24 versus 1.67 ± 0.03, p < 0.001) (NWL:
n = 67; NWO: n = 64). We also analyzed the difference in
vascular inflammation between NWL and NWO subjects
from the total population who were equally matched by
sex and BMI. We observed a significant difference in
the degree of carotid inflammation after matching for
BMI (TBRmean: 1.24 ± 0.25 versus 1.44 ± 0.21, p < 0.001;
TBRmax: 1.42 ± 0.29 versus 1.68 ± 0.32, p < 0.001) (n = 63
in each group). Moreover, we analyzed the vascular
Table 1 Clinical and biochemical characteristics of the study subjects
Total (N = 164) NWL (N = 82) NWO (N = 82) p-value
Age (years) 54.1 ± 9.4 52.9 ± 9.3 55.3 ± 9.4 0.101
Gender (N, (%)) 66 (40) 33 (40) 33 (40) >0.999
Body mass index (kg/m2) 22.7 ± 1.7 21.7 ± 1.6 23.8 ± 0.9 <0.001
Waist to hip ratio 0.87 ± 0.08 0.84 ± 0.08 0.89 ± 0.07 <0.001
Body fat (%) 27.1 ± 5.0 24.1 ± 4.5 30.1 ± 3.3 <0.001
Body fat (kg) 16.2 ± 3.0 14.0 ± 2.6 18.4 ± 1.7 <0.001
Visceral fat (kg) 2.0 ± 0.6 1.6 ± 0.4 2.5 ± 0.4 <0.001
Subcutaneous fat (kg) 14.1 ± 2.7 12.3 ± 2.3 15.9 ± 1.6 <0.001
Muscle mass (kg) 40.5 ± 6.5 41.2 ± 6.9 39.7 ± 6.1 0.147
Systolic BP (mmHg) 121.9 ± 14.9 118.7 ± 14.7 125.1 ± 14.4 0.005
Diastolic BP (mmHg) 76.3 ± 9.4 74.7 ± 9.4 78.0 ± 9.1 0.022
Fasting plasma glucose (mmol/L) 5.24 ± 0.66 4.98 ± 0.46 5.51 ± 0.72 <0.001
HbA1c (%) 5.6 ± 0.5 5.5 ± 0.4 5.7 ± 0.6 0.094
Total cholesterol (mmol/L) 5.12 ± 0.89 5.11 ± 0.90 5.13 ± 0.89 0.859
Triglyceride (mmol/L) 1.14 ± 0.57 1.01 ± 0.51 1.27 ± 0.61 0.003
HDL-cholesterol (mmol/L) 1.37 ± 0.32 1.46 ± 0.35 1.29 ± 0.261 0.001
LDL-cholesterol (mmol/L) 3.14 ± 0.80 3.09 ± 0.80 3.19 ± 0.80 0.397
CRP (mg/L) 1.6 ± 3.1 1.2 ± 3.2 2.0 ± 2.9 0.096
AST (IU/L) 22.4 ± 8.8 22.3 ± 10.6 22.4 ± 6.7 0.916
ALT (IU/L) 22.9 ± 14.5 20.7 ± 11.6 25.2 ± 16.7 0.049
Fatty Liver (N, (%)) 53 (32.3) 14 (17.1) 39 (47.6) <0.001
Antihypertension drug (N, (%)) 24 (17.1) 10 (12.2) 14 (17.1) 0.377
Statin (N, (%)) 14 (8.6) 8 (9.8) 6 (7.3) 0.576
Antiplatelet agent (N, (%)) 15 (9.0) 7 (8.5) 8 (9.8) 0.786
NWL, normal weight lean; NWO, normal weight obesity; N, number; BP, blood pressure; HbA1c, glycated hemoglobin A1c; HDL, high density lipoprotein; LDL, low
density lipoprotein; AST/ALT, aspartate/alanine aminotransferase; CRP, C-reactive protein. Data are presented as mean ± SD or number (percentages). The p values
represent differences between groups determined by an independent two-sample t-test for continuous variables and the χ2 test or the Fisher’s exact test for
categorical variables.
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difference in vascular inflammation in male subjects be-
tween the NWL and NWO groups (TBRmean: 1.33 ± 0.15
versus 1.47 ± 0.16, p = 0.001; TBRmax: 1.50 ± 0.18 versus
1.71 ± 0.22, p < 0.001) and in female subjects between the
NWL and NWO groups (TBRmean: 1.33 ± 0.20 versus
1.43 ± 0.22, p = 0.015; TBRmax: 1.54 ± 0.26 versus 1.65 ±
0.27, p = 0.038) (Table 4).Correlation between the degree of vascular inflammation
and various CVD risk factors
The correlation between vascular inflammation and vari-
ous CVD risk factors was analyzed. Age, BMI, and the fast-
ing plasma glucose level were significantly associated with
both TBRmean and TBRmax (Table 5 and Figures 4A-C,
4E-G). We also analyzed the correlation between vascular
inflammation and fat mass. Total, visceral, and subcutane-
ous fat mass were all significantly correlated with thedegree of vascular inflammation; this degree of correlation
was better than that observed for the traditional CVD
risk factors of age, BMI, and fasting plasma glucose level
(Table 5 and Figure 4D and H). However, none of the
other anthropometric or biochemical characteristics cor-
related with TBRmean or TBRmax.Independent predictors of vascular inflammation
Univariate linear regression analysis followed by multivari-
ate linear regression analysis was performed to determine
the independent predictors of vascular inflammation. For
multivariate linear regression analysis, only the total fat
among other fat parameters was tested together with
other significant parameters because of the multicollinear-
ity. Among the significant parameters identified by univar-
iate linear regression analysis (age, BMI, fasting plasma
glucose level, and total fat amount), the total body fat
amount was the only significant independent predictor
Table 2 Clinical and biochemical characteristics of the study subjects by gender
Men p Women p
Total (N = 66) NWL (N = 33) NWO (N = 33) Total (N = 98) NWL (N = 49) NWO (N = 49)
Age (years) 56.0 ± 9.1 55.5 ± 8.8 56.4 ± 9.6 0.699 52.9 ± 9.5 51.2 ± 9.3 54.6 ± 9.4 0.071
Body mass index (kg/m2) 23.3 ± 1.3 22.4 ± 1.3 24.2 ± 0.6 <0.001 22.3 ± 1.8 21.1 ± 1.5 23.5 ± 1.0 <0.001
Waist to hip ratio 0.94 ± 0.04 0.91 ± 0.04 0.97 ± 0. 02 <0.001 0.82 ± 0.05 0.79 ± 0.05 0.84 ± 0.02 <0.001
Body fat (%) 23.4 ± 4.1 20.2 ± 3.6 26.5 ± 1.0 <0.001 29.6 ± 3.8 26.6 ± 2.9 32.6 ± 1.4 <0.001
Body fat (kg) 15.5 ± 3.2 13.2 ± 2.6 17.9 ± 1.5 <0.001 16.6 ± 3.0 14.5 ± 2.5 18.7 ± 1.7 <0.001
Visceral fat (kg) 2.3 ± 0.6 1.8 ± 0.5 2.8 ± 0.2 <0.001 1.8 ± 0.5 1.4 ± 0.4 2.3 ± 0.3 <0.001
Subcutaneous fat (kg) 13.1 ± 2.6 11.3 ± 2.2 15.0 ± 1.3 <0.001 14.7 ± 2.6 13.0 ± 2.2 16.5 ± 1.5 <0.001
Muscle mass (kg) 47.0 ± 4.6 48.1 ± 4.7 45.9 ± 4.2 0.047 36.1 ± 3.1 36.6 ± 3.4 35.6 ± 2.8 0.122
Systolic BP (mmHg) 125.0 ± 13.7 122.5 ± 13.6 127.6 ± 13.4 0.134 119.8 ± 15.3 116.1 ± 14.9 123.5 ± 15.0 0.017
Diastolic BP (mmHg) 78.9 ± 8.2 77.9 ± 8.3 79.9 ± 8.2 0.319 74.6 ± 9.7 72.5 ± 9.6 76.7 ± 9.5 0.031
Fasting plasma glucose (mmol/L) 5.43 ± 0.66 5.09 ± 0.48 5.76 ± 0.66 <0.001 5.12 ± 0.62 4.90 ± 0.42 5.33 ± 0.71 <0.001
HbA1c (%) 5.7 ± 0.5 5.6 ± 0.4 5.8 ± 0.6 0.245 5.6 ± 0.5 5.5 ± 0.5 5.6 ± 0.5 0.213
Total cholesterol (mmol/L) 5.03 ± 0.95 5.14 ± 1.01 4.93 ± 0.91 0.364 5.19 ± 0.95 5.10 ± 0.84 5.29 ± 0.86 0.283
Triglyceride (mmol/L) 1.36 ± 0.71 0.19 ± 0.68 1.53 ± 0.71 0.048 1.36 ± 0.71 1.19 ± 0.68 1.53 ± 0.71 0.010
HDL-cholesterol (mmol/L) 1.22 ± 0.26 1.31 ± 0.29 1.12 ± 0.20 0.004 1.48 ± 0.31 1.56 ± 0.35 1.41 ± 0.24 0.016
LDL-cholesterol (mmol/L) 3.14 ± 0.85 3.18 ± 0. 89 3.11 ± 0.83 0.756 3.15 ± 0.77 0.04 ± 0.75 3.26 ± 0.79 0.155
CRP (mg/L) 2.4 ± 4.50 1.8 ± 5.1 2.9 ± 4.0 0.322 1.1 ± 1.3 0.8 ± 0.7 1.4 ± 1.6 0.026
AST (IU/L) 24.9 ± 11.6 25.7 ± 14.7 24.1 ± 7.5 0.593 20.6 ± 5.7 20.0 ± 5.6 21.3 ± 5.9 0.271
ALT (IU/L) 27.9 ± 15.0 24.7 ± 12.2 31.1 ± 16.9 0.083 19.6 ± 13.2 18.0 ± 10.5 21.2 ± 15.4 0.239
Fatty Liver (N,%) 29 (44.0) 7 (21.2) 22 (66.7) <0.001 24 (24.5) 7 (14.7) 17 (34.7) 0.019
Antihypertension drug (N, (%)) 15 (22.7) 6 (18.2) 9 (27.3) 0.378 9 (9.2) 4 (8.1) 5 (10.2) >0.999
Statin (N,%) 7 (10.6) 2 (6.1) 5 (15.2) 0.427 7 (7.1) 6 (12.2) 1 (2.0) 0.111
Antiplatelet agent (N,%) 7 (10.6) 1 (21.2) 6 (12.1) 0.105 8 (8.1) 6 (12.2) 2 (4.1) 0.268
NWL, normal weight lean; NWO, normal weight obesity; N, number; BP, blood pressure; HbA1c, glycated hemoglobin A1c; HDL, high density lipoprotein; LDL, low
density lipoprotein; AST/ALT, aspartate/alanine aminotransferase; CRP, C-reactive protein. Data are presented as mean ± SD or number (percentages). The p values
represent differences between groups determined by an independent two-sample t-test for continuous variables and the χ2 test or the Fisher’s exact test for
categorical variables.
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coefficient = 0.020, p = 0.008; TBRmax: regression coef-
ficient = 0.028, p = 0.005) (Table 6).
Association of NWO with the highest risk of subclinical
vascular inflammation
To assess the risk of subclinical atherosclerosis in the sub-
jects between the NWO and NWL groups, we performedTable 3 Comparison of 18 F-FDG-PET/CT results between the N
Total (N = 164)
SUVmean, jugular vein 1.15 ± 0.22
SUVmean, carotid artery 1.59 ± 0.32
SUVmax, carotid artery 1.83 ± 0.38
TBRmean, carotid artery 1.39 ± 0.19
TBRmax, carotid artery 1.60 ± 0.25
NWL, normal weight lean; NWO, normal weight obesity; N, number; SUVmean/max,
target-to-background ratio. Data are presented as mean ± SD. The p values represen
two-sample t-test.multiple logistic regression analysis using a TBRmax value
equal to or greater than the highest quartile as the end-
point. After adjusting for basic clinical factors such as age,
fasting plasma glucose level, systolic BP, HDL-cholesterol
level, LDL-cholesterol level, and triglyceride level, NWO
subjects were 3.1-fold more likely to display subclinical
vascular inflammation (OR = 3.071, 95% confidence inter-
val (CI) = 1.292–7.297, p = 0.011). Moreover, the NWOWL and NWO subjects
NWL (N = 82) NWO (N = 82) p-value
1.16 ± 0.23 1.15 ± 0.22 0.745
1.53 ± 0.31 1.64 ± 0.31 0.024
1.75 ± 0.36 1.90 ± 0.38 0.009
1.33 ± 0.16 1.45 ± 0.19 <0.001
1.52 ± 0.23 1.67 ± 0.25 <0.001
mean/maximum standardized uptake value; TBRmean/max, mean/maximum
t differences between groups determined by the independent
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Figure 2 Scatter plot and comparison of the 18 F-FDG-PET/CT
results between NWL and NWO subjects. A scatter plot of the
18 F-FDG-PET/CT results was drawn, and a comparison between the
NWL and NWO subjects was performed. (A) Carotid mean SUV,
(B) carotid maximum SUV, (C) carotid mean TBR, and (D) carotid
maximum TBR. 18 F-FDG-PET/CT, 18 F-fludeoxyglucose positron
emission tomography/computed tomography; SUV, standardized
uptake value; TBR, target-to-background ratio; NWL, normal weight
lean; NWO, normal weight obesity. Horizontal lines in the graph
indicate means, whereas perpendicular lines denote the standard
deviation. *p < 0.05 versus NWL. #p < 0.001 versus NWL.
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http://www.cardiab.com/content/13/1/70subjects were 2.9-fold more likely to exhibit subclinical
vascular inflammation, even after adjusting for age, fasting
plasma glucose level, systolic BP, HDL-cholesterol level,
LDL-cholesterol level, triglyceride level, and all medication
history concerning CVD (OR = 2.887, 95% CI = 1.206–
6.914, p = 0.017); no other variables significantly contrib-
uted to the vascular inflammation, except for NWO in
these models (Table 7).Discussion
To our knowledge, this is the first study to demonstrate
that compared to NWL subjects, NWO subjects have a
higher degree of vascular inflammation using 18 F-FDG-
PET/CT. Furthermore, the findings also reveal the sig-
nificant contribution of body fat to subclinical vascular
inflammation, even in the normal BMI population. Thus,the main finding of the present study is that more active
and earlier surveillance of subclinical vascular inflamma-
tion may be required to prevent clinical vascular events,
even in patients who were not defined as obese by the
classical definition.
BMI is calculated as the weight divided by the square
of height. Body weight is mainly composed of muscle
mass and fat mass. It is well known that muscle is a type
of endocrine organ, exercise has an anti-inflammatory
effect on vessels, and excess fat mass exerts harmful
effects on vascular inflammation [30,31]. Obesity is prin-
cipally defined as the presence of excess fat mass with
elevated cardiometabolic risk. Therefore, although BMI
is the most easily used and widely accepted criteria for
defining obesity [6], BMI can miscategorize a significant
proportion of subjects who have lower muscle mass con-
tent and higher body fat levels as those having a same
cardiovascular risk as healthy, non-obese subjects [7-10].
Previous studies have indicated the elevation of carotid
artery TBR in obese subjects with BMI values of ≥25 kg/m2
[32] or BMI values of ≥30 kg/m2 [33]. In addition, several
studies identified a persistent positive correlation between
TBR and BMI even after adjusting for confounding factors
[32,34]. However, none of these studies assessed the possi-
bility of NWO, previously classified as not obese, as a po-
tential risk for vascular inflammation. The importance of
our study lies in identifying NWO as a novel risk factor for
increased vascular inflammation and in determining that
body fat itself, rather than BMI, is more important as a
driving force for this subclinical inflammation.
Several reports have indicated that visceral fat may
have a greater harmful effect on vascular inflammation
than subcutaneous fat [35]. When we analyzed the degree
of vascular inflammation in subjects with excess visceral
fat or in subjects with excess subcutaneous fat by gener-
ating new parameters such as “the ratio of visceral-to-
subcutaneous fat amount” or “the ratio of subcutaneous-
to-visceral fat amount,” the value of TBRmean and TBR
max were found to be higher in the subjects with higher
visceral-to-subcutaneous fat ratio and lower in the sub-
jects with higher subcutaneous-to-visceral fat ratio. This
suggests that varying ratios of depot-specific fat amount
may have different effects on vascular inflammation (Data
not shown). Moreover, we suggest that the ratio of
visceral-to-subcutaneous adipose tissue may be essential
for vascular inflammation, even in normal weight subjects.
However, it should be considered that an increment in the
absolute amount of total fat, regardless of whether it in-
volves visceral or subcutaneous fat, may definitely exert a
harmful effect on vascular inflammation, even in normal
weight subjects, as shown in the present data. Although
we could not extensively analyze the depot-specific effect
of body fat on vascular inflammation in normal weight
subjects in the present study, the findings obtained in the
Figure 3 Representative figures indicating the SUV uptake at the carotid artery in NWL and NWO subjects. Coronal image of 18 F-FDG-PET/CT
around the carotid artery is presented as an unenhanced CT image, a fusion image of CT and PET, and a maximum intensity projection (MIP) image,
from the upper panel to the lower panel. The red arrow indicates the carotid artery. 18 F-FDG-PET/CT, 18 F-fludeoxyglucose positron emission
tomography/computed tomography; SUV, standardized uptake value; NWL, normal weight lean; NWO, normal weight obesity.
Table 4 Comparison of 18 F-FDG-PET/CT results between the NWL and NWO subjects by gender
Men p Women P
Total NWL NWO Total NWL NWO
(N = 66) (N = 33) (N = 33) (N = 98) (N = 49) (N = 49)
SUVmean, jugular vein 1.15 ± 0.19 1.18 ± 1.19 1.12 ± 0.19 0.267 1.15 ± 0.24 1.15 ± 0.25 1.16 ± 0.24 0.736
SUVmean, carotid artery 1.60 ± 0.26 1.56 ± 0.28 1.63 ± 0.25 0.232 1.59 ± 0.35 1.52 ± 0.33 1.65 ± 0.35 0.058
SUVmax, carotid artery 1.83 ± 0.33 1.76 ± 0.31 1.90 ± 0.33 0.067 1.82 ± 0.41 1.74 ± 0.40 1.90 ± 0.41 0.057
TBRmean, carotid artery 1.40 ± 0.17 1.33 ± 0.15 1.47 ± 0.16 0.001 1.38 ± 0.22 1.33 ± 0.20 1.43 ± 0.22 0.015
TBRmax, carotid artery 1.60 ± 0.23 1.50 ± 0.18 1.71 ± 0.22 <0.001 1.59 ± 0.27 1.54 ± 0.26 1.65 ± 0.27 0.038
NWL, normal weight lean; NWO, normal weight obesity; N, number; SUVmean/max, mean/maximum standardized uptake value; TBRmean/max, mean/maximum
target-to-background ratio. Data are presented as mean ± SD. The p values represent differences between groups determined by the independent
two-sample t-test.
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Table 5 Correlation between the degree of TBR by
18 F-FDG-PET/CT and various CVD risk factors
TBRmean TBRmax
r p-value r p-value
Age 0.170 0.029 0.165 0.035
Body mass index 0.184 0.018 0.206 0.008
Waist to hip ratio 0.130 0.097 0.123 0.117
Body fat (%) 0.169 0.030 0.200 0.010
Body fat (kg) 0.267 0.001 0.289 <0.0001
Visceral fat (kg) 0.264 0.001 0.278 <0.0001
Subcutaneous fat (kg) 0.240 0.002 0.266 0.001
Muscle mass (kg) 0.056 0.476 0.034 0.668
Systolic BP 0.083 0.292 0.030 0.702
Diastolic BP 0.123 0.117 0.090 0.253
FPG 0.157 0.044 0.182 0.020
HbA1c −0.050 0.597 −0.021 0.825
Total cholesterol 0.064 0.417 0.082 0.296
Triglyceride 0.057 0.467 0.070 0.372
HDL-Cholesterol −0.017 0.832 −0.016 0.843
LDL-Cholesterol 0.050 0.524 0.065 0.408
CRP 0.031 0.700 0.077 0.347
ALT −0.073 0.353 −0.075 0.342
Fatty liver 0.122 0.119 0.103 0.189
SUVmean/max, mean/maximum standardized uptake value; TBRmean/max,
mean/maximum target-to-background ratio; BP, blood pressure; FPG, fasting
plasma glucose; HbA1c, glycated hemoglobin A1c; HDL, high density
lipoprotein; LDL, low density lipoprotein; AST/ALT, aspartate/alanine
aminotransferase; CRP, C-reactive protein. Data are presented as Pearson’s
correlation coefficient (r). p < 0.05 was regarded as statistically significant.
Kang et al. Cardiovascular Diabetology 2014, 13:70 Page 9 of 12
http://www.cardiab.com/content/13/1/70present study indicate that this topic warrants further
investigation.
De Lorenzo et al. reported that the levels of inflamma-
tory cytokines interleukin-6 and tumor necrosis factor-α,
which are secreted by adipose tissue, are elevated in
NWO subjects compared to their NWL counterparts
[12]. These fat-derived inflammatory factors can affect
the development of atherosclerosis [36,37]. In addition,
Yoo et al. suggested that circulating adipocyte fatty acid
binding protein, primarily expressed in adipocytes, is an
independent determinant of vascular inflammation mea-
sured by 18 F-FDG-PET/CT [38]. Moreover, the NWO
population in the present study also exhibited higher
levels of the inflammation marker CRP, although the
difference was not significant. Thus, these findings dem-
onstrate that subclinical vascular inflammation may be
caused by direct or indirect inflammatory signals from
adipose tissue in NWO subjects. NWO subjects may be
genetically predisposed to obesity and elevated cardiovas-
cular risk [39], whereas the regulation of caloric excess
may prohibit the development of obesity and elevationof cardiovascular risk [40]. As subclinical atheroscler-
osis can finally be presented as a clinically significant
cardiovascular event [41], future strategies to identify
susceptible subjects (such as NWO individuals in the
present study) and to develop interventions to prohibit
the development of a cardiovascular event in the popu-
lation with subclinical atherosclerosis are warranted.
These findings also emphasize that it is critical to iden-
tify a useful biomarker for selecting the population at
risk for adipose tissue-associated vascular inflammation,
including subjects with a normal BMI. The usefulness of
the biomarkers may be validated with the non-invasive
18 F-FDG-PET/CT imaging technique as conducted in
our study.
Before the introduction of 18 F-FDG-PET/CT as a non-
invasive imaging tool for visualizing the early inflamma-
tion of atherosclerosis in the vessel, there was no definite
method to detect subclinical atherosclerosis [42,43]. The
current methods such as intima-media thickness, coron-
ary computed tomography angiography, and coronary
angiography mainly evaluate the structural change of the
vessels, which is a manifestation of progressed athero-
sclerosis [44]. In the present analysis, importantly, some
patients in the NWO group had a very high degree of
vascular inflammation (TBRmax > 2.0), a finding that has
not been observed in NWL subjects thus far. Severe in-
flammatory lesions may result in a clinically meaningful
CVD event [45,46]. In addition, studies involving non-
invasive functional imaging of vascular inflammation using
18 F-FDG-PET/CT indicated that these highly inflamma-
tory lesions can serve as targets of earlier intervention in
NWO subjects, the results of which were promising in
a small population [34,47-50]. However, further studies
would need to investigate whether the use of this tech-
nique results in a clinically significant reduction of fu-
ture vascular events.
This study has several limitations. Our study used an
arbitrary cutoff value of BF% based on the tertiles of BF%
to define NWO. However, there is no established cutoff
value for delineating the harmful effect of body fat on a
cardiometabolic event. Therefore, although arbitrary, we
followed the method used in a previously published paper
[14]. Determination of the optimal cutoff value of BF% for
discriminating the subjects at high risk for future CVD
events will be necessary. Second, we used a relatively
simple BI method to evaluate the body fat. However,
there are concerns that the BI method might underesti-
mate upper body obesity [51], and dual energy X-ray ab-
sorptiometry might be more accurate for evaluating BF%.
In contrast, the BI method has several advantages such as
the avoidance of radiation exposure, simplicity, and low
cost, suggesting the utility of BF estimation in large-scale
studies [52]. Third, this study is a cross-sectional study
that cannot confirm a direct causal relationship between
Table 7 Odds ratio for the highest TBRmax (≥ highest
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Figure 4 Correlation between carotid TBR, various clinical factors, and body fat mass. A correlation graph was drawn between the carotid
(A-D) mean or (E-H) maximum TBR and age, BMI, fasting plasma glucose levels, and total body fat. The degree of relationship between putative
CVD risk factors and TBRmean or TBRmax was expressed using Pearson’s correlation coefficient (r). TBR, target-to-background ratio; BMI, body
mass index; FPG, fasting plasma glucose. p < 0.05 was regarded as statistically significant.
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ledge, this is the first study to target the NWO population
specifically in a community-oriented cohort. Furthermore,
this study has a relatively large sample size among studies
on vascular inflammation using 18 F-FDG-PET/CT. Never-
theless, a prospective study with a longer study period is
warranted in the future to confirm whether vascular in-
flammation assessed by 18 F-FDG-PET/CT is actually asso-
ciated with CVD events.
Conclusions
To our knowledge, the present study is the first study to
indicate that NWO subjects, who have increased BF%
compared to NWL subjects, are associated with a higherTable 6 Determinants of carotid TBRmean and TBRmax
TBRmean TBRmax
Regression
coefficient
SE p-value Regression
coefficient
SE p-value
Age 0.003 0.002 0.088 0.003 0.002 0.124
BMI 0.014 0.014 0.339 −0.018 0.019 0.351
FPG 0.001 0.001 0.421 0.002 0.002 0.279
Body fat 0.020 0.007 0.008 0.028 0.010 0.005
TBRmean/max, mean/maximum target-to-background ratio; SE, standard error;
BMI, body mass index; FPG, fasting plasma glucose. Data are presented as the
regression coefficient and standard error. p < 0.05 was regarded as
statistically significant.degree of vascular inflammation using 18 F-FDG-PET/CT,
which enables the noninvasive detection of functional/sub-
clinical vascular inflammation. Furthermore, we suggested
that BF may be a major contributing factor of vascular in-
flammation even in normal weight patients. NWO subjects,
formerly classified as non-obese with the conventional BMI
criteria, may represent a unique subset of patients who
should not be excluded from high-risk groups of future
CVD events. The findings of the present study warrant fu-
ture clinical investigations into the uniqueness of NWO pa-
tients, particularly regarding the potential for future CVD
events.quartile TBRmax)
NWL NWO p-value
odds ratio (95% CI) odds ratio (95% CI)
Model 1 1.00 (reference) 2.384 (1.141–4.982) 0.021
Model 2 1.00 (reference) 3.071 (1.292–7.297) 0.011
Model 3 1.00 (reference) 2.887 (1.206–6.914) 0.017
Model 1, not adjusted; Model 2, adjusted for age, fasting plasma glucose level,
systolic BP, HDL-cholesterol level, LDL-cholesterol level, and triglyceride level;
Model 3, adjusted for age, fasting plasma glucose level, systolic BP, HDL-
cholesterol level, LDL-cholesterol level, triglyceride level, antihypertension drug
use, statin use, and antiplatelet agent use. NWL, normal weight lean; NWO,
normal weight obesity; CI, confidence interval. Data are presented as odds
ratios with the NWL group as a reference (1). p < 0.05 was regarded as
statistically significant.
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